For this reason, SMIs targeting ASPH have been developed, and their anti-tumor activity has been demonstrated in tumor cell lines and animal models.9 However, ASPH inhibition may also affect the immune system, as its targets, particularly Notch receptors, are produced in immune cells. The gene discussed is ASPH; the disease is neoplasm.